A newly surfaced internal memo from the U.S. Food and Drug Administration (FDA) has sparked debate after chief medical and scientific officer Vinay Prasad stated that COVID-19 vaccinations may have contributed to at least 10 cases of fatal heart inflammation in children. According to the memo, seen by Reuters, Prasad said the staff’s preliminary review suggested “likely, probable, or possible” vaccine attribution in these deaths. He described the findings as significant, noting it would mark the first time the FDA acknowledged potential fatal vaccine-related cases in American children.
The analysis reviewed 96 child deaths reported between 2021 and 2024. While it did not identify the children’s underlying medical conditions or the vaccine manufacturers involved, Prasad said that the early assessment found no fewer than 10 cases potentially linked to COVID-19 vaccination. He added that examining deaths involving children aged 7 to 16 was especially difficult.
Health Secretary Robert F. Kennedy Jr. has recently shifted U.S. vaccine policy, restricting access to COVID-19 vaccines to individuals 65 and older and those with certain conditions. Kennedy, long known for his skepticism toward vaccines, has criticized past vaccine policies promoted under both the Trump and Biden administrations.
Experts have urged caution in interpreting the memo. The FDA’s assessment has not been peer-reviewed or published in a medical journal, and critics—including UC Law San Francisco professor Dorit Reiss—argue that policy changes should not stem from unpublished investigations. Reiss also noted Prasad is not a vaccine specialist.
Despite concerns raised in the memo, FDA Commissioner Marty Makary emphasized that COVID-19 vaccines were highly effective for older adults, especially when matched to circulating variants. Recent research also supports the benefits of updated vaccines in reducing severe illness and hospitalization among high-risk groups.
CDC data shows 1,071 U.S. children aged 5 to 18 died from COVID-19 between early 2020 and mid-2023. Prasad argued that it remains unclear how vaccination influenced those outcomes, stating that voluntary reporting and unknown prevention metrics complicate comparisons.
The memo is expected to fuel continued discussion ahead of an upcoming CDC vaccine committee meeting.


Brazil Struggles to Stop Illegal Amazon Gold Mining as Gold Prices Surge
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak
Brazil Extends Fuel Subsidies and Tax Relief Measures Through July 2026 Amid Global Oil Market Volatility
Kosovo Election 2026: Albin Kurti’s Party Wins Most Votes but Falls Short of Majority
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies
UN Blacklists Israel and Russia Over Conflict-Related Sexual Violence Claims
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1
US Tightens AI Chip Export Rules, Impacting Nvidia and AMD Sales to Chinese Firms
Mauritius Rejects Report of Trump Administration Plan to Buy Chagos Islands
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks
Lebanese President Urges Israel to Negotiate End to Conflict, Calls Military Approach Ineffective
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



